{"title":"新冠肺炎与乳腺癌预后：台湾地区无病生存率的比较分析","authors":"Wei-Teng Wang, Pei-Shan Wu, Wan-Chi Hu, Chen-Pin Chou","doi":"10.2147/CMAR.S539849","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluates the effect of pandemic-related diagnostic and treatment delays on 3-year disease-free survival (DFS) in Taiwanese breast cancer patients.</p><p><strong>Material and methods: </strong>This single-institution study analyzed breast cancer patients across three distinct periods: non-COVID-19 in 2017, pre-COVID-19 in 2019, and during the COVID-19 pandemic in 2020, to investigate the impact of the COVID-19 pandemic on DFS rates and recurrence rates. DFS was defined as the interval from surgery to the occurrence of breast cancer recurrence or death, whereas overall survival (OS) was defined as the interval from surgery to death from any cause. Follow-up protocol included regular clinical examinations and annual imaging, with a minimum follow-up of 36 months unless an event occurred earlier.</p><p><strong>Results: </strong>The demographics of breast cancer patients changed from 2017 to 2020, with an average age increasing from 54.6 to 58.6 years. While overall survival (OS) did not vary significantly across the cohorts, DFS differed significantly, with the 2020 cohort experiencing a significant decline in DFS compared to 2017 (p = 0.027). Recurrence rates also increased, from 3.1% in 2017 to 7.6% in 2020.</p><p><strong>Conclusion: </strong>The COVID-19 pandemic had a negative impact on the DFS of breast cancer patients, with the 2020 cohort experiencing a significantly shorter DFS time compared to the 2017 cohort.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"2287-2295"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506798/pdf/","citationCount":"0","resultStr":"{\"title\":\"COVID-19 and Breast Cancer Prognosis: A Comparative Analysis of Disease-Free Survival Rates in Taiwan.\",\"authors\":\"Wei-Teng Wang, Pei-Shan Wu, Wan-Chi Hu, Chen-Pin Chou\",\"doi\":\"10.2147/CMAR.S539849\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study evaluates the effect of pandemic-related diagnostic and treatment delays on 3-year disease-free survival (DFS) in Taiwanese breast cancer patients.</p><p><strong>Material and methods: </strong>This single-institution study analyzed breast cancer patients across three distinct periods: non-COVID-19 in 2017, pre-COVID-19 in 2019, and during the COVID-19 pandemic in 2020, to investigate the impact of the COVID-19 pandemic on DFS rates and recurrence rates. DFS was defined as the interval from surgery to the occurrence of breast cancer recurrence or death, whereas overall survival (OS) was defined as the interval from surgery to death from any cause. Follow-up protocol included regular clinical examinations and annual imaging, with a minimum follow-up of 36 months unless an event occurred earlier.</p><p><strong>Results: </strong>The demographics of breast cancer patients changed from 2017 to 2020, with an average age increasing from 54.6 to 58.6 years. While overall survival (OS) did not vary significantly across the cohorts, DFS differed significantly, with the 2020 cohort experiencing a significant decline in DFS compared to 2017 (p = 0.027). Recurrence rates also increased, from 3.1% in 2017 to 7.6% in 2020.</p><p><strong>Conclusion: </strong>The COVID-19 pandemic had a negative impact on the DFS of breast cancer patients, with the 2020 cohort experiencing a significantly shorter DFS time compared to the 2017 cohort.</p>\",\"PeriodicalId\":9479,\"journal\":{\"name\":\"Cancer Management and Research\",\"volume\":\"17 \",\"pages\":\"2287-2295\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506798/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Management and Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/CMAR.S539849\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S539849","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
COVID-19 and Breast Cancer Prognosis: A Comparative Analysis of Disease-Free Survival Rates in Taiwan.
Purpose: This study evaluates the effect of pandemic-related diagnostic and treatment delays on 3-year disease-free survival (DFS) in Taiwanese breast cancer patients.
Material and methods: This single-institution study analyzed breast cancer patients across three distinct periods: non-COVID-19 in 2017, pre-COVID-19 in 2019, and during the COVID-19 pandemic in 2020, to investigate the impact of the COVID-19 pandemic on DFS rates and recurrence rates. DFS was defined as the interval from surgery to the occurrence of breast cancer recurrence or death, whereas overall survival (OS) was defined as the interval from surgery to death from any cause. Follow-up protocol included regular clinical examinations and annual imaging, with a minimum follow-up of 36 months unless an event occurred earlier.
Results: The demographics of breast cancer patients changed from 2017 to 2020, with an average age increasing from 54.6 to 58.6 years. While overall survival (OS) did not vary significantly across the cohorts, DFS differed significantly, with the 2020 cohort experiencing a significant decline in DFS compared to 2017 (p = 0.027). Recurrence rates also increased, from 3.1% in 2017 to 7.6% in 2020.
Conclusion: The COVID-19 pandemic had a negative impact on the DFS of breast cancer patients, with the 2020 cohort experiencing a significantly shorter DFS time compared to the 2017 cohort.
期刊介绍：
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:
◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
